Claims for Patent: 7,834,054

Summary for Patent: 7,834,054

Title:	Hydroxamates as therapeutic agents
Abstract:	The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
Inventor(s):	Verner; Erik J. (Belmont, CA), Buggy; Joseph J. (Mountain View, CA)
Assignee:	Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:	12/393,923
Patent Claims:	1. A method for treating lung cancer, colon cancer, skin cancer, breast cancer, ovarian cancer, prostate cancer, liver cancer, brain cancer, skin cancer, stomach cancer, pancreatic cancer, neuroblastoma, T-cell lymphoma, or leukemia in a human comprising administering to the human a pharmaceutical composition comprising a therapeutically effective amount of a compound with the following structure: ##STR00026## or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient. 2. The method of claim 1, wherein the leukemia is myelogenous leukemia (MML) or acute myelogenous leukemia (AML). 3. The method of claim 1, wherein the pharmaceutical composition is administered in combination with one or more compound(s) independently selected from an estrogen receptor modulator, an androgen receptor modulator, retinoid receptor modulator, a cytotoxic agent, another antiproliferative agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor, DNA methyltransferase inhibitor, an angiogenesis inhibitor, or an antineoplastic agent. 4. The method of claim 1, further comprising radiation therapy. 5. The method of claim 3, further comprising radiation therapy. 6. The method of claim 3, wherein the one or more compound(s) are independently selected from doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloro-methotrexate, mitomycin C, porfiromycin, Trastuzumab, Rituximab, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin, colchicines, etoposide, etoposide phosphate, teniposide, melphalan, vinblastine, vincristine, leurosidine, vindesine, leurosine, paclitaxel, estramustine, cisplatin, carboplatin, cyclophosphamide, bleomycin, tamoxifen, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT-11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons and interleukins.

Details for Patent 7,834,054

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2023-04-07
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2023-04-07
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2023-04-07
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2023-04-07